Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  History and future of lipid therapeutics- a time of Renaissance
Logo

American Heart Association

  122
  0

Final ID:

History and future of lipid therapeutics- a time of Renaissance

  • Rader, Daniel  ( UNIVERSITY OF PENNSYLVANIA , Philadelphia , Pennsylvania , United States )
  • Morris, Pamela  ( MEDICAL UNIVERSITY OF SC , Mt Pleasant , South Carolina , United States )
    • Author Disclosures:
    Daniel Rader: DO have relevant financial relationships ; Consultant:Alnylam:Active (exists now) ; Consultant:Verve:Active (exists now) ; Consultant:Novartis:Active (exists now) | Pamela Morris: DO have relevant financial relationships ; Researcher:Esperion:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

More abstracts from these authors:
Discussant: VESALIUS-CV trial

Morris Pamela

Hypertension and AI based clinic guidance

Rader Daniel, Khera Amit, Kelly Melissa, Ebinger Joseph

You have to be authorized to contact abstract author. Please, Login
Not Available